Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.
Front Oncol. 2017 Dec 1;7:283. doi: 10.3389/fonc.2017.00283. eCollection 2017.
Front Oncol. 2017.
PMID: 29250484
Free PMC article.
Preliminary characterization of an experimental breast cancer cells brain metastasis mouse model by MRI/MRS.
Simões RV, Martinez-Aranda A, Martín B, Cerdán S, Sierra A, Arús C.
Simões RV, et al. Among authors: martinez aranda a.
MAGMA. 2008 Jul;21(4):237-49. doi: 10.1007/s10334-008-0114-6. Epub 2008 May 31.
MAGMA. 2008.
PMID: 18516631
Free article.
Item in Clipboard
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Martínez-Aranda A, Hernández V, Picón C, Modolell I, Sierra A.
Martínez-Aranda A, et al.
Int J Mol Sci. 2013 Apr 16;14(4):8306-27. doi: 10.3390/ijms14048306.
Int J Mol Sci. 2013.
PMID: 23591844
Free PMC article.
Item in Clipboard
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A.
Martínez-Aranda A, et al.
Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471.
Oncotarget. 2015.
PMID: 26497551
Free PMC article.
Item in Clipboard
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.
Mateo F, et al. Among authors: martinez aranda a.
Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.
Oncogene. 2017.
PMID: 27991928
Free PMC article.
Item in Clipboard
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M, Trinidad EM, Perez-Chacon G, Alsaleem M, Jimenez M, Jimenez-Santos MJ, Perez-Montoyo H, Sanz-Moreno A, Vethencourt A, Toss M, Petit A, Soler-Monso MT, Lopez V, Gomez-Miragaya J, Gomez-Aleza C, Dobrolecki LE, Lewis MT, Bruna A, Mouron S, Quintela-Fandino M, Al-Shahrour F, Martinez-Aranda A, Sierra A, Green AR, Rakha E, Gonzalez-Suarez E.
Ciscar M, et al. Among authors: martinez aranda a.
EMBO Mol Med. 2023 Apr 11;15(4):e16715. doi: 10.15252/emmm.202216715. Epub 2023 Mar 7.
EMBO Mol Med. 2023.
PMID: 36880458
Free PMC article.
Item in Clipboard
Cite
Cite